• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients.

作者信息

Del Poeta Giovanni, Bomben Riccardo, Polesel Jerry, Rossi Francesca Maria, Pozzo Federico, Zaina Eva, Cattarossi Ilaria, Varaschin Paola, Nanni Paola, Boschian Boschin Romina, Postorino Massimiliano, Laureana Roberta, Pasqualone Gianmario, Steffan Agostino, Gentile Massimo, Zucchetto Antonella, Gattei Valter

机构信息

Division of Hematology, University of Tor Vergata, Rome, Italy.

Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.

出版信息

Hematol Oncol. 2021 Dec;39(5):712-714. doi: 10.1002/hon.2916. Epub 2021 Aug 30.

DOI:10.1002/hon.2916
PMID:34462939
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8652757/
Abstract
摘要

相似文献

1
COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients.2019冠状病毒病疫苗接种：慢性淋巴细胞白血病患者疫苗接种失败风险评估
Hematol Oncol. 2021 Dec;39(5):712-714. doi: 10.1002/hon.2916. Epub 2021 Aug 30.
2
Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者接种第二剂BNT162b mRNA新冠疫苗100天后的抗体持久性
Leukemia. 2021 Sep;35(9):2727-2730. doi: 10.1038/s41375-021-01380-5. Epub 2021 Aug 10.
3
mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis.慢性淋巴细胞白血病患者接种新型冠状病毒 mRNA 疫苗：一项系统评价与荟萃分析。
Eur J Haematol. 2022 Mar;108(3):264-267. doi: 10.1111/ejh.13729. Epub 2021 Dec 13.
4
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia.慢性淋巴细胞白血病患者在接受第一剂和第二剂 COVID-19 疫苗后的抗体反应。
Blood Cancer J. 2021 Jul 30;11(7):136. doi: 10.1038/s41408-021-00528-x.
5
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.2019冠状病毒病疫苗对慢性淋巴细胞白血病患者的疗效
Leukemia. 2021 Sep;35(9):2703-2705. doi: 10.1038/s41375-021-01270-w. Epub 2021 May 13.
6
Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.血液学和肿瘤学患者中BNT162b2 mRNA新冠疫苗的血清学SARS-CoV-2抗体反应、潜在预测标志物及安全性
Br J Haematol. 2021 Nov;195(4):523-531. doi: 10.1111/bjh.17743. Epub 2021 Aug 3.
7
Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.慢性髓系肿瘤患者对新冠病毒疫苗接种的抗体反应受损。
Br J Haematol. 2021 Sep;194(6):1010-1015. doi: 10.1111/bjh.17644. Epub 2021 Jun 24.
8
Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者 COVID-19 疫苗失败的原因和后果。
Eur J Haematol. 2022 Feb;108(2):91-98. doi: 10.1111/ejh.13722. Epub 2021 Dec 5.
9
Preserved antibody responses to COVID-19 vaccination and lower odds of developing COVID-19 in adults with severe asthma.重度哮喘成人对新冠疫苗接种的抗体反应得以维持，且感染新冠的几率较低。
J Allergy Clin Immunol Pract. 2024 Sep;12(9):2510-2513.e2. doi: 10.1016/j.jaip.2024.05.026. Epub 2024 May 23.
10
Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?接受BNT162b2 mRNA疫苗或AZD1222疫苗的健康志愿者中针对SARS-CoV-2的中和抗体反应比较：AZD1222疫苗的第二剂是否应提前接种？
Am J Hematol. 2021 Sep 1;96(9):E321-E324. doi: 10.1002/ajh.26248. Epub 2021 Jun 2.

引用本文的文献

1
Immune response dynamics of SARS-CoV-2 vaccination in chronic lymphocytic leukemia individuals: a descriptive analysis.慢性淋巴细胞白血病患者中SARS-CoV-2疫苗接种的免疫反应动力学：一项描述性分析
Front Immunol. 2025 Jun 6;16:1571680. doi: 10.3389/fimmu.2025.1571680. eCollection 2025.
2
Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病的疫苗挑战：对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）免疫接种对慢性淋巴细胞白血病患者疗效的全面探索
Ann Hematol. 2024 Dec;103(12):4971-4980. doi: 10.1007/s00277-024-05869-8. Epub 2024 Jul 15.
3
Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights.管理和治疗血液系统恶性肿瘤患者的 COVID-19：叙述性综述和专家观点。
Clin Exp Med. 2024 Jun 4;24(1):119. doi: 10.1007/s10238-024-01381-5.
4
Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile Subjects.细胞和体液免疫反应的整合作为健康和脆弱人群中 SARS-CoV-2 疫苗接种的免疫监测工具。
Viruses. 2023 May 30;15(6):1276. doi: 10.3390/v15061276.
5
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis.成年癌症患者对新冠病毒疫苗全程接种和加强针的体液免疫反应受损，尤其是正在接受积极治疗的血液系统癌症患者：一项系统评价和荟萃分析。
Cancers (Basel). 2023 Apr 12;15(8):2266. doi: 10.3390/cancers15082266.
6
Serological and cellular response to mRNA-SARS-CoV2 vaccine in patients with hematological lymphoid malignancies: Results of the study "Cervax".血液系统淋巴恶性肿瘤患者对mRNA-SARS-CoV2疫苗的血清学和细胞反应：“Cervax”研究结果
Front Oncol. 2023 Feb 27;13:1133348. doi: 10.3389/fonc.2023.1133348. eCollection 2023.
7
COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia.2019冠状病毒病疫苗接种反应及其在慢性淋巴细胞白血病患者中的实际应用
Hemasphere. 2022 Dec 20;7(1):e811. doi: 10.1097/HS9.0000000000000811. eCollection 2023 Jan.
8
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis.免疫原性和与血液恶性肿瘤患者在接种 SARS-CoV-2 疫苗和加强针后免疫反应受损相关的风险：一项更新的荟萃分析。
Blood Cancer J. 2022 Dec 23;12(12):173. doi: 10.1038/s41408-022-00776-5.
9
Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect.布鲁顿酪氨酸激酶抑制剂在B细胞淋巴瘤中的作用：超越抗肿瘤效应
Exp Hematol Oncol. 2022 Sep 22;11(1):60. doi: 10.1186/s40164-022-00315-9.
10
A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.一项系统评价和荟萃分析：成人血液恶性肿瘤患者对 SARS-CoV-2 疫苗首剂和第 2 剂的免疫应答。
Int Immunopharmacol. 2022 Sep;110:109046. doi: 10.1016/j.intimp.2022.109046. Epub 2022 Jul 12.

本文引用的文献

1
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.2019冠状病毒病疫苗对慢性淋巴细胞白血病患者的疗效
Leukemia. 2021 Sep;35(9):2703-2705. doi: 10.1038/s41375-021-01270-w. Epub 2021 May 13.
2
A global database of COVID-19 vaccinations.一个全球 COVID-19 疫苗接种数据库。
Nat Hum Behav. 2021 Jul;5(7):947-953. doi: 10.1038/s41562-021-01122-8. Epub 2021 May 10.
3
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.BNT162b2 mRNA新冠疫苗在慢性淋巴细胞白血病患者中的疗效
Blood. 2021 Jun 10;137(23):3165-3173. doi: 10.1182/blood.2021011568.
4
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.慢性淋巴细胞白血病患者的 COVID-19 严重程度和死亡率：ERIC、欧洲慢性淋巴细胞白血病研究倡议和 CLL 校园的联合研究。
Leukemia. 2020 Sep;34(9):2354-2363. doi: 10.1038/s41375-020-0959-x. Epub 2020 Jul 9.
5
Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL).对慢性淋巴细胞白血病（CLL）患者的结合型肺炎球菌疫苗（PCV13）的反应。
Leukemia. 2021 Mar;35(3):737-746. doi: 10.1038/s41375-020-0884-z. Epub 2020 Jun 17.
6
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression.CD49d 促进慢性淋巴细胞白血病的疾病进展：来自 CD49d 双模态表达的新见解。
Blood. 2020 Apr 9;135(15):1244-1254. doi: 10.1182/blood.2019003179.